Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
Communiqués de presse de la société MERCK & CO., INC.
01/13MERCK : Confirms Agreement with UNICEF to Establish the World's First Global Ebo..
PU
01/12EISAI : To present data on lenvima monotherapy and in combination with keytruda ..
AQ
01/12MERCK : U.S. FDA Accepts for Priority Review the Biologics License Application f..
BU
01/11MERCK : to Hold Fourth-Quarter and Full-Year 2020 Sales and Earnings Conference ..
AQ
01/08MERCK : to Hold Fourth-Quarter and Full-Year 2020 Sales and Earnings Conference ..
BU
01/04MERCK : to Present at the 39th Annual J.P. Morgan Healthcare Conference
BU
2020MERCK : LYNPARZA Receives Three New Approvals in Japan
AQ
2020MERCK : LYNPARZA® (olaparib) Receives Three New Approvals in Japan
BU
2020MERCK : FDA's Oncologic Drugs Advisory Committee to Discuss Merck's Application ..
PU
2020MERCK : Announces Supply Agreement with U.S. Government for Initial Doses of Inv..
BU
2020MERCK : FDA Grants Priority Review to Merck's Supplemental Biologics License App..
AQ
2020EISAI : LENVIMA plus KEYTRUDA Combination Demonstrated Statistically Significant..
AQ
2020MERCK : KEYTRUDA plus LENVIMA Combination Demonstrated Statistically Significant..
AQ
2020MERCK : FDA Grants Priority Review to Merck's Supplemental Biologics License App..
BU
2020MERCK : KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Demonst..
BU
2020MERCK : Receives Positive EU CHMP Opinion for KEYTRUDA as First-Line Treatment i..
AQ
2020ATTACKING DIVISIONAL PATENTS : Is A New Approach Emerging?
AQ
2020MERCK : Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as First..
BU
2020MERCK : Announces Sale of its Direct Equity Investment in Moderna
PU
2020MERCK : to Present at the 2020 Evercore ISI 3rd Annual HealthCONx Virtual Confer..
BU
2020OF MOLECULES & MEDICINE : Dr Maurice Hilleman ("The Father Of Modern Vaccines")
AQ
2020MERCK : Submits Applications for Licensure of V114, the Company's Investigationa..
AQ
2020CORCEPT THERAPEUTICS INCORPORATED : Appoints Gillian M. Cannon, PhD, to Board of..
AQ
2020MERCK : to Acquire OncoImmune
AQ
2020MERCK : Submits Applications for Licensure of V114, the Company's Investigationa..
BU
2020MERCK : to Acquire OncoImmune
BU
2020EISAI : To present new investigational data on lenvima in thyroid cancer and ost..
AQ
2020IMMUTEP : Announces Expansion of TACTI-002 Collaboration Trial
AQ
2020MERCK : Announces First-Quarter 2021 Dividend
AQ
2020MERCK : Unveils New Website for Global Study for Monitoring Antimicrobial Resist..
PU
2020The Veterinary Vaccines Market Expected to Grow at $11.80 Billion by 2028
AQ
2020MERCK : Announces First-Quarter 2021 Dividend
BU
2020MERCK : Advances Phase 3 trial to Evaluate Investigational Islatravir as Once-Mo..
AQ
2020MERCK : FDA Approves Merck's KEYTRUDA in Combination with Chemotherapy for Patie..
AQ
2020MERCK : Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Mo..
BU
2020MERCK : FDA Approves Merck's KEYTRUDA® (pembrolizumab) in Combination With Chemo..
BU
2020MERCK : Keytruda plus lenvima demonstrated statistically significant improvement..
AQ
2020EISAI : LENVIMA plus KEYTRUDA Demonstrated Statistically Significant Improvement..
AQ
2020EISAI : Lenvima plus Keytruda achieves primary endpoints in trial for RCC
AQ
2020MERCK : KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Statis..
BU
2020MERCK : Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Comb..
BU
2020EISAI : Announces investigational data highlighting lenvima based combination th..
AQ
2020MERCK : Thinking about trading options or stock in General Electric, Merck, Roku..
PR
2020PAPPAS CAPITAL : Portfolio Company VelosBio to be Acquired by Merck
PR
2020MERCK : LYNPARZA® (olaparib) Approved in the EU for Treatment of BRCA1/2-Mutated..
BU
2020MERCK : LYNPARZA® (olaparib) in Combination with Bevacizumab Approved in the EU ..
BU
2020MERCK : to Acquire VelosBio
BU
2020SANOFI : to evaluate the safety and efficacy of novel investigational candidate ..
AQ
2020MERCK : Announces Third-Quarter 2020 Financial Results
AQ
2020MERCK : Phil Deploys 76 Community Health Mobilizers in Montserrado
AQ
2020MERCK : Strong sales of drugs, vaccines, propel Merck in 3Q
AQ
2020MERCK : 3Q20 Merck Other Financial Disclosures
PU
2020MERCK : 3Q20 Merck Earnings Presentation
PU
2020MERCK : Strong sales of drugs, vaccines, propel Merck in 3Q
AQ
2020MERCK : 3Q Earnings Snapshot
AQ
2020MERCK & CO., INC. : Results of Operations and Financial Condition, Financial Sta..
AQ
2020MERCK : Announces Third-Quarter 2020 Financial Results
BU
2020MERCK : Donates $500,000 to Support River Blindness and Lymphatic Filariasis Eli..
AQ
2020MERCK : PHIL, MERCK Partner to Reach Girls With HPV Vaccine
AQ
2020MERCK : Donates $500,000 to Support River Blindness and Lymphatic Filariasis Eli..
BU
2020MERCK : Announces Positive Topline Results from Two Additional Phase 3 Adult Stu..
AQ
2020SANOFI : Merck and Sanofi to Present Three New Studies Highlighting Combination ..
AQ
2020MERCK : to Present New Data from its Extensive Infectious Diseases and Vaccines ..
BU
2020MERCK : and Sanofi to Present Three New Studies Highlighting Combination Pediatr..
PU
2020MERCK : Announces Positive Topline Results from Two Additional Phase 3 Adult Stu..
BU
2020MERCK : Presents Three-Year Survival Data for KEYTRUDA® (pembrolizumab) in Combi..
BU
2020MERCK : FDA Approves Expanded Indication for Merck's KEYTRUDA in Adult Patients ..
AQ
2020MERCK : Issues 2019, 2020 Corporate Responsibility Report
AQ
2020MERCK : Health Canada Approves KEYTRUDA® (pembrolizumab) as First-line Treatment..
AQ
2020MERCK : FDA Approves Expanded Indication for Merck's KEYTRUDA® (pembrolizumab) i..
BU
2020MERCK : Announces Plans to Construct New Facility in the United States to Expand..
PU
2020MERCK : Issues 2019/2020 Corporate Responsibility Report
BU
2020MERCK : Intec Pharma Announces New Research Collaboration Agreement with MSD
AQ
2020MODERNA : Announces Updates on Respiratory Syncytial Virus Vaccine Program
AQ
2020MERCK : Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Comb..
BU
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on MERCK & CO., INC.